Skip to main content
SpringerLink
Log in

Systemic Treatment of Advanced or Metastatic Soft Tissue Sarcomas

  • Chapter
Soft Tissue Sarcomas: New Developments in the Multidisciplinary Approach to Treatment

Part of the book series: Cancer Treatment and Research ((CTAR,volume 56))

Abstract

Adequate local treatment of soft tissue sarcomas has always been difficult in view of the local recurrence rate of 40 to 80% [1]. Most of these relapses occur within 3 years [2]. The use of sophisticated surgical techniques and the addition of postoperative high-dose radiotherapy have considerably reduced the number of local recurrences in extremity lesions [2–5]. Unfortunately, the inability to apply the required high doses of irradiation precluded a similar decrease in local recurrence in truncal lesions after surgery. Early hematogeneous spreading, most frequently to the lungs, is characteristic for soft tissue sarcomas and apparently can only in part be prevented by optimal local control of the primary tumor. Therefore, distant metastases still occur in a considerable number of patients for whom systemic treatment will be considered. This chapter summarizes the present achievements with systemic treatment of advanced soft tissue sarcomas.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Enneking WF, Spanier SS, Malawer MM: The effect of the anatomic setting on the results of surgical procedures for soft-part sarcomas of the thigh. Cancer 47:1005–1022, 1981.

    Article  PubMed  CAS  Google Scholar 

  2. Lindberg RD, Martin RG, Ramsdahl MM: Surgery and postoperative radiotherapy in the treatment of soft tissue sarcomas in adults. AJR Ther Nucl Med 123:123–129, 1975.

    CAS  Google Scholar 

  3. Gerson R, Shiu MH, Hajdu SI: Sarcoma of the buttock: A trend toward limb-salvage resection. J Surg Oncol 19:238–242, 1982.

    Article  PubMed  CAS  Google Scholar 

  4. Leibel SA, Tranbaugh RF, Wara WM, et al.: Soft tissue sarcomas of the extremities: Survival and patterns of failure with conservative surgery and postoperative irradiation compared to surgery alone. Cancer 50:1076–1083, 1982.

    Article  PubMed  CAS  Google Scholar 

  5. Suit HD, Mankin HJ, Wood WC, Proppe KH: Preoperative, intraoperative, and postoperative radiation in the treatment of primary soft tissue sarcoma. Cancer 55:2659–2667,1985.

    Article  PubMed  CAS  Google Scholar 

  6. Bonadonna G, Beretta G, Tanchini G, et al.: Adriamycin (NSC-123127) studies at the Instituto Nazionale Tumori, Milan. Cancer Chemother Rep 6:231–245, 1975.

    Google Scholar 

  7. Verweij J, van Oosterom AT, Pinedo HM: Melanomas, soft tissue and bone sarcomas. Eur J Cancer Clin Oncol 4 (Suppl):75–85, 1985.

    Google Scholar 

  8. Borden EC, Amato DA, Rosenbaum Ch, et al.: Randomized comparison of three adria-mycin regiments for metastatic soft tissue sarcomas. J Clin Oncol 5:840–850, 1987.

    PubMed  CAS  Google Scholar 

  9. Santoro A, Rouëssé J, Steward W, Mouridsen H, Verweij J, Somers R, Blackledge G, Buesa J, Sayer J, Casali P, Thomas D, Sylvester R: A randomized EORTC phase III study comparing adriamycin vs A plus ifosfamide vs CYVADIC in advanced soft tissue sarcoma. Proc ECCO 5:438, 1989.

    Google Scholar 

  10. Blackledge G, van Oosterom A, Mouridsen H, Steward WP, Buesa J, Thomas D, Sylvester R, Rouëssé J: Doxorubicin in relapsed soft tissue sarcoma: Justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group study. Eur J Cancer Clin Oncol, in press.

    Google Scholar 

  11. O’Bryan RM, Luce JK, Talley RW: Phase II evaluation of adriamycin in human neo-plasma. Cancer 32:1–8, 1973.

    Article  PubMed  Google Scholar 

  12. Mitts DL, Gerhardt H, Armstrong D, et al.: Chemotherapy for advanced soft tissue sarcomas: Results of phase I and II cooperative studies. Tex Med 75:43–47, 1979.

    PubMed  CAS  Google Scholar 

  13. Chlebowski RT, Paroly WS, Pugh RP: Adriamycin given as a weekly schedule without a loading course: Clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 64:49–51, 1980.

    Google Scholar 

  14. Benjamin RS, Yap BS: Infusion chemotherapy for soft tissue sarcomas. In: Soft tissue sarcomas. Baker LH (ed). Boston: Martinus Nijhoff, pp 109–116, 1983.

    Chapter  Google Scholar 

  15. Samuels BL, Vogelzang NJ, Ruane M, Simon MA: Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treat Rep 71:971–972, 1987.

    PubMed  CAS  Google Scholar 

  16. Gerlach JH, Bell DR, Karakousis C, et al.: P-glycoprotein in human sarcoma: Evidence for multidrug resistance. J Clin Oncol 5:1452–1460, 1987.

    PubMed  CAS  Google Scholar 

  17. Mouridsen HT, Bastholt L, Somers R, Santoro A, Bramwell V, Mulder JH, van Oosterom AT, Buesa J, Pinedo HM, Thomas D, Sylvester R: Adriamycin versus epirubicin in advanced soft tissue sarcomas: A randomized phase Il/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 23:1477–1483, 1987.

    Article  PubMed  CAS  Google Scholar 

  18. Chevallier B, Monteuquet PH, Fachini T, Bui B, Tanguy A, Kerbrat P, Bastit PH, Hurteloup P: Phase II study of epirubicin in advanced soft tissue sarcoma. Proc Am Soc Clin Oncol 8:323, 1988.

    Google Scholar 

  19. Bodey GP, Yap BS, Ajani J: Clinical trials of 4’epidoxorubicin. Proc 13th Int Congr Chemother 215:23–26, 1983.

    Google Scholar 

  20. Bramwell VHC, Mouridsen HT, Mulder JH, Somers R, van Oosterom AT, Santoro A, Thomas D, Sylvester R, Markham D: Carminomycin vs adriamycin in advanced soft tissue sarcomas: An EORTC randomized phase II study. Eur J Cancer Clin Oncol 19:1097–1104, 1983.

    Article  PubMed  CAS  Google Scholar 

  21. Bertrand M, Multhauf P, Bartolucci A, Ellison D, Gockerman J: Phase II study of aclarubicin in previously untreated patients with advanced soft tissue sarcoma: A South-Eastern Cancer Study Group trial. Cancer Treat Rep 69:725–726, 1985.

    PubMed  CAS  Google Scholar 

  22. Pazdur R, Samson MK, Baker LH: Aclacinomycin: Phase II evaluation in advanced soft tissue sarcoma. Am J Clin Oncol 10:237–239, 1987.

    Article  PubMed  CAS  Google Scholar 

  23. Raymond V, Magill GB, Wissel PS, Cheng WE, Ochoa M, Young CW: Phase II trial of deoxydoxorubicin in patients with soft tissue sarcoma. Proc Am Soc Clin Oncol 5:146, 1986.

    Google Scholar 

  24. Wissel PS, Magill GB, Raymond V, Well S, Sordillo P, Cheng E: 4′Demethoxydauno-rubicin in advanced soft tissue sarcomas: An update with emphasis on patients without prior doxorubicin. Proc Am Soc Clin Oncol 3:259, 1984.

    Google Scholar 

  25. Buckner JC, Edmonson JH, Ingle JN, Schaid DJ: Evaluation of menogaril in patients with metastatic sarcomas and no prior chemotherapy exposure. Am J Clin Oncol 12:384–386, 1989.

    Article  PubMed  CAS  Google Scholar 

  26. Presant CA, Gans R, Bartolucci AA: Treatment of metastatic sarcomas with mitoxantrone. Cancer Treat Rep 68:813–814, 1984.

    PubMed  CAS  Google Scholar 

  27. Bull FE, von Hoff DD, Balcerzak SP, Stephens RL, Panetierre FJ: Phase II trial of mitoxantrone in advanced sarcomas: a South-West Oncology Group study. Cancer Treat Rep 69:231–233, 1985.

    PubMed  CAS  Google Scholar 

  28. Gottlieb JA, Benjamin RS, Baker LH, et al.: Role of DTIC (NSC-45338) in the chemotherapy of sarcomas. Cancer Treat Rep 60:199–203, 1976.

    PubMed  CAS  Google Scholar 

  29. Buesa J, Mouridsen H, van Oosterom AT, Steward WT, Verweij J, Thomas D: High-dose DTIC in advanced soft tissue sarcoma of the adult: A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Proc ECCO 4:235, 1987.

    Google Scholar 

  30. Hoefer-Janker H, Scheef W, Gunther U, et al.: Erfahrungen mit der fraktionierten Ifosfamid-Stoss Therapie bei generalisierten malignen Tumoren. Med Welt 26:972–979, 1977.

    Google Scholar 

  31. Klein HO, Wickramanayake PD, Coerper CL, et al.: High-dose ifosfamide and mesna as continuous infusion over five days: A phase I/II trial. Cancer Treat Rev 10:167–173, 1983.

    Article  PubMed  Google Scholar 

  32. Czownicki A, Utracka-Hutka B: Contribution to the treatment of malignant tumours with ifosfamide. In: Proceedings of the international Holoxan symposium. Burkert H, Voight HC (eds). Dusseldorf: ASTA-Werke, pp 109–111, 1977.

    Google Scholar 

  33. Antman KM, Montella D, Rosenbaum CH, Schwen M: Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep 68:499–504, 1985.

    Google Scholar 

  34. Wiltshaw E, Westburg G, Harmer C, McKinna A, Fisher C: Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. Cancer Chemother Pharmacol 18(Suppl 2):S10–12, 1986.

    Article  Google Scholar 

  35. Bramwell VHC, Mouridsen H, Santoro A, Blackledge G, Somers R, Verweij J, Domber-nowsky P, Onsrud M, Thomas D, Sylvester R, van Oosterom AT: Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23:311–321, 1987.

    Article  PubMed  CAS  Google Scholar 

  36. Legha S, Papadopoulos N, Usakewicz J, Fenoglio C, Nicaise C, Benjamin R: Role of ifosfamide in the treatment of refractory sarcomas and an evaluation of N-acetylcysteine as a uroprotector. Proc Am Soc Clin Oncol 9:322, 1989.

    Google Scholar 

  37. Quirt I, Eisenhauer E, Knowling M, Warr D, Bramwell V, Rusthoven J, Wierzbicki R, Verna S: A phase II study of Trimetrexate in metastatic soft tissue sarcoma. Proc Am Soc Clin Oncol 7:275, 1988.

    Google Scholar 

  38. Sordillo PP, Magill GB, Brenner J, Cheng EW, Dosik M, Yagoda A: A phase II evaluation of cisplatin in previously untreated patients with soft tissue sarcomas. Cancer 59:884–886, 1987.

    Article  PubMed  CAS  Google Scholar 

  39. Budd GT, Balcerzak S, Mortimer J, Fletcher W: SWOG 8465: High-dose cisplatin for advanced sarcomas. Proc Am Soc Clin Oncol 6:137, 1987.

    Google Scholar 

  40. Thigpen JT, Blessing JA, Wilbanks GD: Cisplatin as second-line chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus: A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol (CCT) 9:18–20, 1986.

    Article  CAS  Google Scholar 

  41. Sordillo PP, Magill GB, Welt S: Phase II trial of methylglyoxal-bis guanylhydrazone (methyl-GAG) in patients with soft-tissue sarcomas. Am J Clin Oncol (CCT) 8:316–318, 1985.

    Article  CAS  Google Scholar 

  42. Thigpen JT, Blessing JA, Homesley HD, Hacker N, Curry SL: Phase II trial of piper-azinedione in patients with advanced or recurrent uterine sarcoma: A Gynecologic Oncology Group study. Am J Clin Oncol (CCT) 8:350–352, 1985.

    Article  CAS  Google Scholar 

  43. Amato DA, Borden EC, Shiraki M, Enterline HT, Rosenbaum C, Davis HL, Paul AR, Stevens CM, Lerner HJ: Evaluation of bleomycin, chlorozotocin, MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma, and mesothelioma. Invest New Drugs 3:397–401, 1985.

    Article  PubMed  CAS  Google Scholar 

  44. Chan C, Bartolucci A, Brenner D, Presant C, Davila E, Carpenter J, Greco A, Clamon G, Moore J: Phase II trial of diaziquone in anthracycline-resistant adult soft tissue and bone sarcoma patients: A South-Eastern Cancer Study Group trial. Cancer Treat Rep 70:427–428, 1986.

    PubMed  CAS  Google Scholar 

  45. Cowan JD, Gehan E, Rivkin SE, Jones SE: Phase II trial of bisantrene in patients with advanced sarcoma: A South-West Oncology Group study. Cancer Treat Rep 70:685–686, 1986.

    PubMed  CAS  Google Scholar 

  46. Wissel P, Magill G, Sordillo P, Cheng E, Hakes T, Applewhite A: A phase II trial of mitomycin C in advanced soft tissue sarcomas. Proc Am Soc Clin Oncol 5:146, 1986.

    Google Scholar 

  47. Ajani JA, Dimery I, Chawla SP, Pinnamaneni K, Benjamin RS, Legha S, Krakoff IH: Phase II studies of homoharringtonine in patients with advanced malignant melanomas, sarcoma, and head and neck, breast and colorectal carcinomas. Cancer Treat Rep 70:375–379, 1986.

    PubMed  CAS  Google Scholar 

  48. Rouëssé JG, van Oosterom AT, Capellaere P, Kerbrat P, van Groeningen CJ, Thomas D, Benshahar D: Phase II study of 1,2,4-triglycidyl urasol (TGU) in advanced soft tissue sarcoma: A trial of the EORTC Soft Tissue and Bone Sarcoma Cooperative Group. Eur J Cancer Clin Oncol 23:1413–1414, 1987.

    Article  PubMed  Google Scholar 

  49. Dombernowsky P, Buesa J, Pinedo HM, Santoro A, Mouridsen HT, Somers R, Bramwell V, Onsrud M, Rouëssé J, Thomas D, Sylvester R: VP-16 in advanced soft tissue sarcoma: A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 23:579–580, 1987.

    Article  PubMed  CAS  Google Scholar 

  50. Zalupski M, Pazdur R, Samson M, Baker L: Phase II clinical evaluation of fludarabine in soft tissue and osteosarcomas. Proc Am Soc Clin Oncol 6:135, 1987.

    Google Scholar 

  51. Pazdur R, Samson MK, Baker L: Fludarabine phosphate; Phase II evaluation in advanced soft tissue sarcomas. Am J Clin OnCol 10:341–343, 1987.

    CAS  Google Scholar 

  52. Blackledge G, Verweij J, Füchs R, Keizer J, Rodenhuis C, Rankin E, Kerbrat P, van Oosterom A, Sylvester R, Thomas D and Rouëssé J: A phase II study of M-azido-pyrimethamine ethane sulphonate (MZPES) in advanced recurrent soft tissue sarcoma: An EORTC Soft Tissue and Bone Sarcoma Group study. Eur J Cancer Clin Oncol, in press.

    Google Scholar 

  53. Steward WP, Mouridsen HT, Kerbrat P, Somers R, Verweij J, van Oosterom AT, Black-ledge G, Thomas D, Sylvester R: Phase II trial of methylene-dimethane sulphonate (MDMS) in advanced soft tissue sarcomas of the adult. Eur J Cancer Clin Oncol 25:1251-1253, 1989.

    Google Scholar 

  54. Thigpen JT, Blessing JA, Orr JW, DiSaia J: Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: A gynecologic Oncology Group study. Cancer Treat Rep 70:271–271, 1986.

    PubMed  CAS  Google Scholar 

  55. Gershenson DM, Kavanagh JJ, Copeland LJ, Edwardo CL, Stringer CA, Wharton JT: Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus. J Clin Oncol 5:618–621, 1987.

    PubMed  CAS  Google Scholar 

  56. Morrow CP, Bundy BN, Hoffman J, Sutton G, Homesley H: Adriamycin chemotherapy for malignant mixed mesodermal tumor of the uterus. Am J Clin Oncol (CCT) 9:24–26, 1986.

    Article  CAS  Google Scholar 

  57. Gershenson DM, Kavanagh JJ, Copeland LJ, Edwards CL, Freedman RS, Wharton JT: High-dose doxorubicin infusion therapy for disseminated mixed mesodermal sarcoma of the uterus. Cancer 59:1264–1267, 1987.

    Article  PubMed  CAS  Google Scholar 

  58. Harris J, Das Gupta T, Vogelzang N, Badrinath K, Bonomi P, Desser R, Locker G, Blough R, Johnson C: Treatment of soft tissue sarcoma with fibroblast interferon (beta-interferon): An American Cancer Society/Illinois Cancer Council study. Cancer Treat Rep 70:293–294, 1986.

    PubMed  CAS  Google Scholar 

  59. Edmonson JH, Long HJ, Creagan ET, Frytak S, Sherwin SA, Chang MN: Phase II study of recombinant gamma-interferon in patients with advanced non-osseous sarcomas. Cancer Treat Rep 71:211–213, 1987.

    PubMed  CAS  Google Scholar 

  60. Salem P, Zikiwski A, Benjamin RS, Wallace S, Levitt D, Mavligit G: Arterial infusion of interleukin-2 for treatment of hepatic métastases from GI leiomyosarcoma: Predisposition to hypersensitivity to iodine-containing media. Proc Am Soc Clin Oncol 8:322, 1989.

    Google Scholar 

  61. Gottlieb JA, Baker LH, Quagliana JM, Luce JK, Whitecar JP, Sinkovics JG, Rivkin SE, Brownlee R, Frei E: Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide. Cancer 30:1632–1638, 1972.

    Article  PubMed  CAS  Google Scholar 

  62. Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT, Zaino RJ: A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52:626–632, 1983.

    Article  PubMed  CAS  Google Scholar 

  63. Schoenfeld DA, Rosenbaum CH, Horton J, Wolter JM, Falkson G, De Conti RC: A comparison of adriamycin versus vincristine and adriamycin and cyclophosphamide versus vincristine, actinomycin-D and cyclosphosphamide for advanced sarcoma. Cancer 50:2757–2762, 1982.

    Article  PubMed  CAS  Google Scholar 

  64. Muss HB, Bundy B, DiSaia PJ, Homesley HD, Fowler WC, Creasman W, Yordan E: Treatment of recurrent or advanced uterine sarcoma: A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 55:1648–1653, 1985.

    Article  PubMed  CAS  Google Scholar 

  65. Baker LH, Frank J, Fine G, Balcerak SP, Stephens RL, Stuckey WJ, Rivkin S, Saiki J, Ward JH: Combination chemotherapy using adriamycin, DTIC, cyclophosphamide and actinomycin-D for advanced soft tissue sarcomas: A randomized comparative trial — a phase III Southwest Oncology Group study (7613). J Clin Oncol 5:851–861, 1987.

    PubMed  CAS  Google Scholar 

  66. Saiki JH, Baker LH, Rivkin SE, Shahbender S, Fletcher WS, Athens JW, Balcerak SP, Bonnet JD: A useful high-dose intermittent schedule of adriamycin and DTIC in the treatment of advanced sarcomas. Cancer 58:2196–2197, 1986.

    Article  PubMed  CAS  Google Scholar 

  67. Baker LH, Green S, Ryan J, Rosenberg B, Balcerak S: SWOG 8024: Combined modality therapy for disseminated soft tissue sarcoma, phase III. Proc Am Soc Clin Oncol 6:138, 1987.

    Google Scholar 

  68. Yap BS, Baker LH, Sinkovics JG, Rivkin SE, Bottomley R, Thigpen T, Burgess MA, Benjamin RS, Bodey GP: Cyclophosphamide, vincristine, adriamycin and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Rep 64:93–98, 1980.

    PubMed  CAS  Google Scholar 

  69. Yap BS, Burgess MA, Sinkovics JG, Benjamin RS, Bodey GP: A 5-year experience with cyclophosphamide, vincristine, adriamycin and DTIC (CYVADIC) chemotherapy in 169 adults with advanced soft tissue sarcoma. Proc Am Soc Clin Oncol 22:534, 1981.

    Google Scholar 

  70. Yap BS, Sinkovics JG, Burgess MA, Benjamin RS, Bodey GP: The curability of advanced soft tissue sarcomas in adults with chemotherapy. Proc Am Soc Clin Oncol 2:239, 1983.

    Google Scholar 

  71. Pinedo HM, Bramwell VHC, Mouridsen H, Somers R, Vendrik CPJ, Santoro A, Buesa J, Wagener TH, van Oosterom AT, van Unnik JAM, Sylvester R, de Pauw M, Thomas D, Bonadonna G: CYVADIC in advanced soft tissue sarcoma: A randomized study comparing two schedules. Cancer 53:1825–1832, 1984.

    Article  PubMed  CAS  Google Scholar 

  72. Karakousis CP, Rao U, Park HG: Combination chemotherapy (CYVADIC) in metastatic soft tissue sarcomas. Eur J Cancer Clin Oncol 18:33–36, 1982.

    Article  PubMed  CAS  Google Scholar 

  73. Kerzel W, Köning HJ, Walter M, Arnold I: Zytostatische Kombinationsbehandlung fortgeschrittener Sarkome: Ergebnisse einer prospektiv angelegten Studie. Tumor Diagn Ther 6:180–184, 1985.

    Google Scholar 

  74. Bui NB, Chauvergne J, Hocke C, Durand M, Brunet R, Coindre JM: Analysis of a series of sixty soft tissue sarcomas in adults treated with a cyclophosphamide-vincristine-adriamycin-dacarbazine (CYVADIC) combination. Cancer Chemother Pharmacol 15:82–85, 1985.

    PubMed  CAS  Google Scholar 

  75. Schuette J, Mouridsen H, Santoro A, Steward W, van Oosterom AT, Somers R, Black-ledge G, Verweij J, Rouëssé J, Green JA, Pinedo HM, Kaye SB, Kerbrat H, Wagener T, Thomas D, Sylvester R: Adriamycin and ifosfamide, a new effective combination in advanced soft tissue sarcoma. Proc ECCO 4:232, 1987.

    Google Scholar 

  76. Cantwell BMJ, Carmichael J, Ghani S, Harris AL: A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma. Cancer Chemother Pharmacol 21:49–52, 1988.

    Article  PubMed  CAS  Google Scholar 

  77. Loehrer PJ, Sledge GW, Nicaise C, Usakewicz J, Hainsworth JD, Martelo OJ, Omura G, Braun TJ: Ifosfamide plus doxuribicin in metastatic adult sarcomas: A multi-institutional phase II trial. J Clin Oncol 7:1655–1659, 1989.

    PubMed  Google Scholar 

  78. Frustaci S, Foladore S, Lo Re G, Fosser V, Nascimben O, Tuveri G, Magri MD, Mon-fardini S: Full doses of ifosfamide and epirubicin in advanced soft tissue sarcomas. Proc Am Soc Clin Oncol 8:319, 1989.

    Google Scholar 

  79. Elias AD, Ryan L, Aisner J, Antman KH: Doxorubicin, ifosfamide and DTIC (AID) for advanced untreated sarcomas. Proc Am Soc Clin Oncol 6:134, 1987.

    Google Scholar 

  80. Bramwell V, Quirt I, Warr D, Verma S, Young V, Knowling M, Eisenhauer E: Combination chemotherapy with doxorubicin, dacarbazine and ifosfamide in advanced adult soft tissue sarcoma. J Natl Cancer Inst 81:1496–1499, 1989.

    Article  PubMed  CAS  Google Scholar 

  81. Klippstein TH, Mitrou PS, Kochendörfer KJ, Bergmann L: High dose adriamycin and cisplatinum in advanced soft tissue sarcomas and invasive thymomas: A pilot study. Cancer Chemother Pharmacol 13:78–81, 1984.

    Article  PubMed  CAS  Google Scholar 

  82. Hartlapp JH, Munch HJ, Illinger HJ, Wolter H, Jensen JC: Alternatives to CYVADIC combination therapy of soft tissue sarcomas. Cancer Chemother Pharmacol 18(Suppl 2): S20-S23, 1986.

    Google Scholar 

  83. Edmonson JH, Hahn RG, Schutt AJ, Bisel HF, Ingle JN: Cyclophosphamide, doxorubicin and cisplatin combined in the treatment of advanced sarcomas. Med Pediatr Oncol 11:319–321, 1983.

    Article  PubMed  CAS  Google Scholar 

  84. Piver MS, Lele SB, Patsner B: Cisdiamminedichloro-platinum plus dimethyl-triazenoi-midazole carboxamide as second-and third-line chemotherapy for sarcomas of the female pelvis. Gynecol Oncol 23:371–375, 1983.

    Article  Google Scholar 

  85. Seltzer V, Kaplan B, Vogl S, Spitzer M: Doxorubicin and cisplatin in the treatment of advanced mixed mesodermal uterine sarcoma. Cancer Treat Rep 68:1389–1390, 1984.

    PubMed  CAS  Google Scholar 

  86. Moore N, Fine S, Sturgeon J: Malignant mixed mesodermal tumors of the ovary: The Princess Margaret Hospital experience. Proc Am Soc Clin Oncol 5:114, 1986.

    Google Scholar 

  87. Jansen RLH, van der Burg MEL, Verweij J, Stoter G: Cyclophosphamide, hexamethylme-lamine, adriamycin and cisplatin combination chemotherapy in mixed mesodermal sarcoma of the female genital tract. Eur J Cancer Clin Oncol 23:1131–1133, 1987.

    Article  PubMed  CAS  Google Scholar 

  88. Rouëssé JG, Friedman S, Sevin DM, Le Chevalier TH, Spielmann ML, Contesso G, Sarrazin DM, Genin JR: Preoperative induction chemotherapy in the treatment of locally advanced soft tissue sarcomas. Cancer 60:296–300, 1987.

    Article  PubMed  Google Scholar 

  89. Lagarde C, Bui NB, Marée D, Coindre JP, Kantor G, Bussières E: Locally advanced soft tissue sarcomas. Preliminary results of a multi-disciplinary approach with initial (neo-adjuvant) chemotherapy in a series of 46 patients. Proc Am Soc Clin Oncol 7:274, 1988.

    Google Scholar 

Download references

Authors
  1. Jaap Verweij
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Herbert M. Pinedo
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Free University Hospital, Amsterdam, The Netherlands

    Herbert M. Pinedo

  2. Department of Medical Oncology, Rotterdam Cancer Institute, Rotterdam, The Netherlands

    Jaap Verweij

  3. Department of Radiation Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

    Herman D. Suit

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer Science+Business Media New York

About this chapter

Cite this chapter

Verweij, J., Pinedo, H.M. (1991). Systemic Treatment of Advanced or Metastatic Soft Tissue Sarcomas. In: Pinedo, H.M., Verweij, J., Suit, H.D. (eds) Soft Tissue Sarcomas: New Developments in the Multidisciplinary Approach to Treatment. Cancer Treatment and Research, vol 56. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3896-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3896-7_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6738-3

  • Online ISBN: 978-1-4615-3896-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation